178 related articles for article (PubMed ID: 35599263)
1. The effects of Epigallocatechin-3-gallate and Dabrafenib combination on apoptosis and the genes involved in epigenetic events in anaplastic thyroid cancer cells.
Birden N; Selvi Gunel N; Ozates NP; Goker Bagca B; Gunduz C; Sabour Takanlou L; Sabour Takanlou M; Biray Avci C
Med Oncol; 2022 May; 39(5):98. PubMed ID: 35599263
[TBL] [Abstract][Full Text] [Related]
2. Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling.
Liao Y; Gao Y; Chang A; Li Z; Wang H; Cao J; Gu W; Tang R
J Cell Mol Med; 2020 Oct; 24(20):12119-12130. PubMed ID: 32935463
[TBL] [Abstract][Full Text] [Related]
3. Effects of nutraceuticals on anaplastic thyroid cancer cells.
Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
[TBL] [Abstract][Full Text] [Related]
4. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex.
Lim YC; Cha YY
J Surg Oncol; 2011 Dec; 104(7):776-80. PubMed ID: 21725973
[TBL] [Abstract][Full Text] [Related]
6. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines.
De Amicis F; Perri A; Vizza D; Russo A; Panno ML; Bonofiglio D; Giordano C; Mauro L; Aquila S; Tramontano D; Andò S
J Cell Physiol; 2013 Oct; 228(10):2054-62. PubMed ID: 23553645
[TBL] [Abstract][Full Text] [Related]
8. The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer.
Yang L; Zhang W; Chopra S; Kaur D; Wang H; Li M; Chen P; Zhang W
Curr Drug Targets; 2020; 21(11):1099-1104. PubMed ID: 32364072
[TBL] [Abstract][Full Text] [Related]
9. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
10. Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes.
Goker B; Caliskan C; Onur Caglar H; Kayabasi C; Balci T; Erbaykent Tepedelen B; Aygunes D; Yilmaz Susluer S; Mutlu Z; Selvi Gunel N; Korkmaz M; Saydam G; Gunduz C; Biray Avci C
J BUON; 2014; 19(4):992-8. PubMed ID: 25536607
[TBL] [Abstract][Full Text] [Related]
11. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
12. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.
Fang MZ; Wang Y; Ai N; Hou Z; Sun Y; Lu H; Welsh W; Yang CS
Cancer Res; 2003 Nov; 63(22):7563-70. PubMed ID: 14633667
[TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.
Nandakumar V; Vaid M; Katiyar SK
Carcinogenesis; 2011 Apr; 32(4):537-44. PubMed ID: 21209038
[TBL] [Abstract][Full Text] [Related]
14. A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells.
Meeran SM; Patel SN; Chan TH; Tollefsbol TO
Cancer Prev Res (Phila); 2011 Aug; 4(8):1243-54. PubMed ID: 21411498
[TBL] [Abstract][Full Text] [Related]
15. Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
Borutinskaitė V; Virkšaitė A; Gudelytė G; Navakauskienė R
Leuk Lymphoma; 2018 Feb; 59(2):469-478. PubMed ID: 28641467
[TBL] [Abstract][Full Text] [Related]
16. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins.
Nishikawa T; Nakajima T; Moriguchi M; Jo M; Sekoguchi S; Ishii M; Takashima H; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
J Hepatol; 2006 Jun; 44(6):1074-82. PubMed ID: 16481065
[TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin-3-gallate promotes apoptosis in human breast cancer T47D cells through down-regulation of PI3K/AKT and Telomerase.
Moradzadeh M; Hosseini A; Erfanian S; Rezaei H
Pharmacol Rep; 2017 Oct; 69(5):924-928. PubMed ID: 28646740
[TBL] [Abstract][Full Text] [Related]
18. The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells.
Mayr C; Wagner A; Neureiter D; Pichler M; Jakab M; Illig R; Berr F; Kiesslich T
BMC Complement Altern Med; 2015 Jun; 15():194. PubMed ID: 26100134
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
[TBL] [Abstract][Full Text] [Related]
20. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
